Zinc Supplementation With Botulinum Toxin for Overactive Bladder

NCT07405554

Status	RECRUITING
Phase	Phase 2
Sponsor	Endeavor Health
Enrollment	72 participants

Key Eligibility Criteria

Inclusion (8)

- Non-pregnant adult female at least 21 years old, with no plans to become pregnant during the course of the trial) and if of child-bearing potential, with a negative pregnancy test, and if sexually active, must be using medically acceptable contraception.
- e 6urgency urinary incontinence episodes on a 3-day baseline bladder diary, with these urge incontinence episodes representing greater than 50% of the total incontinent episodes recorded.
- Willing and able to complete all study related items and interviews.
- Refractory urgency urinary incontinence: defined as persistent symptoms despite at least one or more conservative treatments (e.g. supervised behavioral therapy, supervised physical therapy)
- Persistent symptoms despite the use of a minimum of two anticholinergics, or unable to tolerate medication due to side effects, or has a contraindication to taking anticholinergic/Beta 3 agonist medication.

... and 3 more (see full listing online)

Exclusion (11)

- Neurologic diseases such as multiple sclerosis, Parkinson Disease, CVA within 6 months prior to enrollment, myasthenia gravis, Charcot-Marie-Tooth disease, clinically significant peripheral neuropathy, and complete spinal cord injury.
- Untreated urinary tract infection (UTI).
- Any prior use of either study therapy for treatment of urinary urge incontinence (Botox A® or Interstim®).
- PVR \>150 ml on 2 occasions within 6 months prior to enrollment (If the PVR value was obtained by ultrasound and was e150 ml, the PVR will be confirmed by catheterization which will be the gold standard).
- Current or prior bladder malignancy.

... and 6 more (see full listing online)

Locations (1 total)

Endeavor Health, Skokie, Illinois, United States